VYNE Investor Relations Presentation
VYNE-Investor-Presentation
VYNE TherapeuticsRooted in Innovation
VYNE Therapeutics
VYNE-Investor-Presentation
KOL Event – Novel InhiBET BET Inhibitor Platform
Current report
Annual report [Section 13 and 15(d), not S-K Item 405]
Prospectuses and communications, business combinations
Current report
Statement of changes in beneficial ownership of securities
Statement of changes in beneficial ownership of securities